|
LymphoCide
LymphoCide
information and resources from the National Cancer Institute
LymphoCide
(Other name for: epratuzumab)lymphokine-activated killer cells
Killer cell lymphocytes activated in the presence of interleukin-2 (IL-2). Lymphokine-activated killer cells (LAKs) are cytotoxic effector cells with an exceptionally wide target cell spectrum including normal and malignant cells of different origins. LAK cells exhibit a profound heterogeneity with regard to phenotype surface marker expression; it remains to be determined if they represent a unique cell lineage. LymphoCide
(Other name for: epratuzumab)
|
|
|
|
|
|
LymphoCide
-->
|
